| Premenopausal | Postmenopausal | ||||||
---|---|---|---|---|---|---|---|---|
 | A1A1 | A1/A2 and A2A2 | A1A1 | A1/A2 and A2A2 | ||||
 | Case/Control | ORa (95% CI) | Case/Control | ORa (95% CI) | Case/Control | ORa (95% CI) | Case/Control | ORa (95% CI) |
Age at menarche | Â | Â | Â | Â | Â | Â | Â | Â |
< 13 yr | 25/11 | 1.0 | 23/26 | 1.0 | 19/25 | 1.0 | 32/25 | 1.0 |
≥ 13 yr | 64/89 | 0.28 (0.10–0.71) | 75/104 | 0.77 (0.39–1.53) | 119/103 | 1.31 (0.63–2.72) | 190/161 | 0.84 (0.44–1.61) |
Postmenopausal use of estrogen | Â | Â | Â | Â | Â | Â | Â | Â |
Never | Â | Â | Â | Â | 100/89 | 1.0 | 154/119 | 1.0 |
Ever |  |  |  |  | 39/40 | 1.15 (0.63–2.12) | 67/66 | 0.86 (0.52–1.41) |
Use of oral contraceptives | Â | Â | Â | Â | Â | Â | Â | Â |
Never | 28/27 | 1.0 | 33/32 | 1.0 | 106/86 | 1.0 | 192/130 | 1.0 |
Ever | 64/74 | 1.01 (0.45–2.27) | 62/97 | 0.55 (0.29–1.03) | 32/41 | 0.83 (0.41–1.74) | 30/57 | 0.52 (0.29–0.98) |
Parity | Â | Â | Â | Â | Â | Â | Â | Â |
Nulliparous | 21/9 | 1.0 | 14/15 | 1.0 | 30/16 | 1.0 | 51/25 | 1.0 |
Parous | 68/91 | 0.26 (0.10–0.60) | 84/115 | 0.77 (0.32–1.94) | 109/109 | 0.53 (0.25–1.08) | 170/164 | 0.97 (0.36–1.17) |
Age at FFTP for parous women | Â | Â | Â | Â | Â | Â | Â | Â |
≤ 25 yr | 48/47 | 1.0 | 51/66 | 1.0 | 65/64 | 1.0 | 105/119 | 1.0 |
> 25 yr | 22/35 | 0.83 (0.45–1.55) | 33/43 | 1.34 (0.61–2.89) | 43/42 | 0.92 (0.53–1.65) | 64/63 | 0.59 (0.28–1.47) |
BMI | Â | Â | Â | Â | Â | Â | Â | Â |
≤ 25,4 | 63/67 | 1.0 | 51/76 | 1.0 | 53/51 | 1.0 | 76/77 | 1.0 |
> 25,4 | 28/35 | 0.60 (0.27–1.34) | 45/52 | 1.05 (0.57–1.93) | 86/76 | 1.43 (0.75–2.72) | 145/110 | 1.64 (0.97–2.78) |
WHR | Â | Â | Â | Â | Â | Â | Â | Â |
< 0,91 | 41/58 | 1.0 | 42/72 | 1.0 | 47/58 | 1.0 | 86/82 | 1.0 |
≥ 0,91 | 47/40 | 1.61 (0.83–3.17) | 57/60 | 1.52 (0.85–2.75) | 91/68 | 1.68 (0.95–2.99) | 136/106 | 1.12 (0.70–1.97) |